Bifidobacterium bifidum G9-1 and Reduced Severity of Gastrointestinal Disorders

Doses used in studies

mg/day: 12 (median 12, IQR 12–12) — 1 study

Time to effect

Median: 2.8 months · IQR 2.8 months–2.8 months · Range 2.8 months–2.8 months — Reported in 1 of 1 study

1 of 1 paper

Bifidobacterium bifidum G9-1 Intake Improves Gastrointestinal Symptoms in Type 2 Diabetes Mellitus: An Open-Label, Randomized Controlled Trial (Binary STAR Study).

2026-04-22
RCT · n = 100
Diabetes, obesity & metabolism 28(7)
- Genki Kobayashi
- Yoshitaka Hashimoto
- Tomoyuki Matsuyama
- Noriyuki Kitagawa
- Saori Majima
- Takafumi Senmaru
- Emi Ushigome
- Hiroshi Okada
- Naoko Nakanishi
- Masahide Hamaguchi
- Michiaki Fukui

PubMed: 42017290
DOI: 10.1111/dom.70805

5 Insights on

Reduced Severity of Gastrointestinal Disorders

High evidence
Large Human Trial
Clinical

BBG9-1 intake significantly improved the GSRS total score (from 2.22 ± 0.67 to 1.83 ± 0.62) compared with control (from 2.08 ± 0.67 to 2.06 ± 0.63; between-group difference, -0.34 [95% CI: -0.55 to -0.14; p = 0.001]).

Effect: Beneficial
Effect size: Small
Significant: Yes
Dose: 12 mg/day